Shows
MedEdTalks - OphthalmologyThe Retina Radar With Dr. Arshad Khanani: DR Management in 2024 With Dr. Carl RegilloIn this podcast, expert clinicians will discuss current and emerging treatment options that may improve outcomes for patients with diabetic retinopathy (DR). https://healio.com/cme/mededtalks/ophthalmology/20240910/5-the-retina-radar-with-dr-arshad-khanani-dr-management-in-2024-with-dr-carl-regillo2024-09-3032 min
Retina SynthesisThe Davio 2 Trial for Neovascular AMDWe review the 6 month results of the Davio 2 trial of the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.2024-05-3113 min
Eye on Ocular HealthMaking the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits
Host: Jennifer I. Lim, MD, FARVO
Guest: Carl Regillo, MD
What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with neovascular age-related macular degeneration and diabetic macular edema. 2024-04-3000 minEye on Ocular HealthMaking the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
Host: Carl Regillo, MD
Guest: Jennifer I. Lim, MD, FARVO
What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as they discuss the biomarkers of Ang-2 and VEGF-A suppression. Hear how to achieve earlier and faster fluid resolution in both neovascular age-related macular degeneration and diabetic macular edema.2024-04-1500 minRetina SynthesisThe Port Delivery System for Treating Diabetic RetinopathyWe discuss the use of the PDS in the treatment of diabetic retinopathy and diabetic macular edema with Professor Carl Regillo of the Wills Eye Hospital.2023-09-2116 min
PER SpectivesMultidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease CareOptometrists play a critical role in first-line screening and monitoring of patients with neovascular age-related macular degeneration (or nAMD) and diabetic macular edema (or DME). Where patients require more advanced care, optometrists refer them to retina specialists. Join Drs Ferhina Ali, Carl Regillo, Jessica Steen and Mohammad Rafieetary as they review the role of optometrists in managing retina disease, the role of OCT in the diagnosis and monitoring of retina disease, and the circumstances where patients with retina disease require referral.
Faculty
Carl D. Regillo, MD, FACS
Retina Surgeon
Philadelphia, PA
Mohammad...2023-08-3027 min
The Retina Channel PodcastE70-Archway 3 Port Delivery System for wAMD- Dr. Carl RegilloDr. Regillo describes the results of the phase 3 prospective study of Ranibizumab Port Delivery System (PDS) for the treatment of neovascular AMD. Reference Article: Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, Callaway NF, DeGraaf S, Ding HT, Fung AE, Gune S, Le Pogam S, Smith R, Willis JR, Barteselli G. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul;130(7):735-747. doi: 10.1016/j.ophtha.2023.02.024. Epub 2023 Mar 2. PMID: 36870451.2023-07-2630 min
MedEdTalks - OphthalmologyLong-acting Injectables in RVO Management With Drs. Carl Regillo and Christina Weng In this podcast, expert clinicians will discuss long-acting injectables in RVO management.2023-06-1517 min
MedEdTalks - OphthalmologyLong-acting Injectables in DME Management With Drs. Carl Regillo and Dilsher Dhoot In this podcast, expert clinicians will discuss long-acting injectables in DME management.2023-06-1518 min
MedEdTalks - OphthalmologyLong-acting Injectables in nAMD Management With Drs. Carl Regillo and Jennifer Lim In this podcast, expert clinicians will discuss long-acting injectables in nAMD management.2023-06-1519 min
New Retina Radio by EyetubeASRS Meeting Coverage: Day 1Treat-and-extend regimens has been used for thousands of wet AMD patients. How does brolucizumab (Beovu, Novartis) stack up when compared with aflibercept (Eylea, Regeneron) in a matched treat-and-extend study? New Retina Radio spoke with Carl Regillo, MD, a member of the TALON study group, which sought to find out if brolucizumab was superior to aflibercept for extending treatment intervals in wet AMD patients. We also spoke with Carl Danzig, MD, whose work on the TRUCKEE study illuminates real-world treatment dynamics when it comes to the use of faricimab (Vabysmo, Genentech) in wet AMD treatment. How ar...2022-07-2826 min
MedEdTalks - OphthalmologyTargeting Angiopoietin-2 in DME: Efficacy and Safety Data With Drs. Carl Regillo and Nancy HolekampThe angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this p...2022-05-3116 minMedEdTalks - OphthalmologyTargeting Angiopoietin-2 in nAMD: Efficacy and Safety Data With Drs. Carl Regillo and Arshad KhananiThe angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this...2022-05-3120 minMedEdTalks - OphthalmologyThe Tie2 Pathway and Its Role in the Pathophysiology of Retinal Vascular Disease With Drs. Carl Regillo and Judy KimThe angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this p...2022-05-3113 minRetina SynthesisLate Breaking News on Kodiak Dazzle TrialWe review the results of the KS-301 wet macular degeneration trial with Dr. Carl Regillo,Chief of the Retina Service at Wills Eye Hospital2022-02-2412 minRetina SynthesisThe Susvimo Sustained Delivery System for Neovascular AMDWe discuss the use of the newly approved Susvimo system for sustained delivery of ranibizumab in the treatment of neovascular AMD with Carl Regillo, MD, Professor of Ophthalmology Thomas Jefferson University and Director of the Retina Service at the Wills Eye Hospital.2022-01-2718 minNew Retina Radio by EyetubeMatching Patients to Therapy in Wet AMD: How New Technology May Alleviate Treatment BurdenIn the first of this three-part series reviewing topics in wet AMD, Carl Regillo, MD, and Adrienne Scott, MD, join moderator John Kitchens, MD, to submit a pair of real-world patient cases illustrating how the need to reduce the burden of care may drive treatment decisions in patients with wet AMD. After they reveal how they managed their respective patient cases, Drs. Regillo and Scott join Dr. Kitchens for a review of how the latest innovations in retina could improve patients’ lives by alleviating treatment burden.This editorially independent podcast is supported with advertising.2021-12-1424 min
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio PodcastCarl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic RetinopathyGo online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even...2021-11-271h 34
PeerView Endocrinology & Diabetes CME/CNE/CPE Video PodcastCarl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic RetinopathyGo online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even...2021-11-271h 34
PeerView Family Medicine & General Practice CME/CNE/CPE Audio PodcastCarl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic RetinopathyGo online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even...2021-11-271h 34
PeerView Clinical Pharmacology CME/CNE/CPE VideoCarl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic RetinopathyGo online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even...2021-11-271h 34
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastCarl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic RetinopathyGo online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even...2021-11-271h 34
PeerView Family Medicine & General Practice CME/CNE/CPE Video PodcastCarl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic RetinopathyGo online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even...2021-11-271h 34
PeerView Internal Medicine CME/CNE/CPE Audio PodcastCarl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic RetinopathyGo online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even...2021-11-271h 34
PeerView Internal Medicine CME/CNE/CPE Video PodcastCarl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic RetinopathyGo online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even...2021-11-271h 34
HCPLive PodcastsPort Delivery System 101 with Carl Regillo, MDThe Director of Retina Services at Wills Eye Hospital joins to discuss the historic FDA approval granted for a novel method of ophthalmic care: a permanent implant that allows for vision-saving formula therapy to treat the eye continually.
Read more about the PDS approval here.
Episode notes:
0:12 Intro
1:07 What is the Port Delivery System?
2:39 The history of developing the PDS
17:00 Is PDS exclusive to anti-VEGF?
19:52 Thoughts on the ranbizumab PDS approval
23:10 How will guidelines change?
24:15 Tips for best PDS use
26:30 Closing thoughts
29:40 Outro2021-11-1630 minNew Retina Radio by EyetubeSurgical options for treating AMD: Clinical Implications and ImpactIn the third episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Carl Awh, MD, and Dante Pieramici, MD, about surgical options for neovascular AMD and how they might be applied in clinical practice. Although some of these options are still in the later stages of development, the panel looks forward to options that may truly change the treatment paradigm for the better. Click here to listen to this and other episodes in this series.This editorially independent podcast is supported with advertising.2021-07-2931 minNew Retina Radio by EyetubeReconsidering treatment endpoints in real-world clinical practice: is achieving a favorable retreatment interval a goal of therapy?In the second episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Jennifer Lim, MD, and Charlie Wykoff, MD, PhD, about the challenges inherent to finding the best retreatment interval for each patient. The panel also shares thoughts on how clinical trials could be structured to deliver data that would help clinicians understand durability of existing and new and novel treatment options. Click here to listen to this and other episodes in this series.This editorially independent podcast is supported with advertising.2021-07-0924 minMedEdTalks - OphthalmologyAchieving Vascular Stability through Inhibition of Ang-2 in AMD and DME, With Nancy M. Holekamp, MD, and Carl D. Regillo, MD, FACSIn this podcast, expert clinicians will discuss achieving vascular stability through inhibition of Ang-2. To obtain CME credit, go here: https://tinyurl.com/y58538ef 2021-07-0118 minMedEdTalks - OphthalmologyEmerging Delivery Systems in Neovascular Retinal Disease: Focus on Devices, With Nancy M. Holekamp, MD, and Carl D. Regillo, MD, FACSIn this podcast, expert clinicians will discuss emerging delivery system devices in neovascular retinal disease. To obtain CME credit, please go here: https://tinyurl.com/thma9fwp2021-06-3015 minNew Retina Radio by EyetubeReal-world impact of patients lost to follow-up: factors that drive nonadherence and strategies for encouraging better follow-up from patientsIn this episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Margaret Chang, MD, and David Eichenbaum, MD, about the consequences of missed injection appointments and less than ideal adherence to monitoring among patients with neovascular AMD. Listen in as the experts discuss some of the challenges inherent to treating patients in real-world practice and share insights on strategies for encouraging adherence.This editorially independent podcast is supported with advertising.2021-06-1131 minMedEdTalks - OphthalmologyCurbside Consults on Retinal Vein Occlusion Management: Treating RVO Early to Improve OutcomesRetinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden...2021-06-0220 minMedEdTalks - OphthalmologyCurbside Consults on Retinal Vein Occlusion Management: Use of Imaging in the Diagnosis of RVORetinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden...2021-06-0222 minMedEdTalks - OphthalmologyCurbside Consults on Retinal Vein Occlusion Management: Use of Imaging in Monitoring Treatment Response in RVORetinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden...2021-06-0218 minMedEdTalks - OphthalmologyCurbside Consults on Retinal Vein Occlusion Management: Deciphering New Data on RVO Treatment – How Do they Affect Real World Practice?Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden...2021-06-0210 minNew Retina Radio by EyetubeAngiogenesis 2021: Wet AMDWhich upcoming therapies will extend duration for patients with wet AMD? John Kitchens, MD, sits down with Diana Do, MD, and Carl Regillo, MD, to hear about their presentations at this year’s Angiogenesis, Exudation, and Degeneration annual meeting. After the break, Drs. Kitchens, Do, and Regillo discuss how the future of wet AMD therapies may alter clinical care for patients undergoing treatment. This editorially independent podcast is supported with advertising.2021-03-1238 minRetina SynthesisFocus on Carl Regillo, MD, and PDS SystemJoin us as Dr. Carmen Puliafito joins in a discussion with Carl Regillo, MD, Director of Retina Serivce, Wills Eye Institute on the topic of Phase 3 Results from the Port Delivery System (PDS) Phase 3 Trial.2021-03-0716 min
Straight From The Cutter's Mouth: A Retina PodcastEpisode 281: Highlights From Angiogenesis 2021, including discussion of port delivery system, gene therapy for geographic atrophy, home OCT monitoring, and faricimab for AMDDrs. Carl Regillo, Nadia Waheed, Anat Loewenstein, and Jeffrey Heier join to discuss their respective talks at the Angiogenesis 2021 meeting, including the port delivery system phase 3 results, gene therapy for geographic atrophy, home OCT monitoring with artificial intelligence, and faricimab phase 3 results for AMD.2021-02-1830 minNew Retina Radio by Eyetube[Back to Practice] Telemedicine & Combating Patient MisinformationThe COVID-19 pandemic accelerated the use of telemedicine. How has this held up in retina now that we’ve had more than 6 months of experience under our belts? New Retina Radio host John Kitchens, MD, invites Judy E. Kim, MD; Byron Ladd, MD; and Carl D. Regillo, MD, to review how their practices have used (or not used) telemedicine during the pandemic. Also, Dr. Kitchens asks the panel how they’ve handled educating patients about the pandemic—and how they’ve tackled questions of misinformation. This editorially independent podcast is supported with advertising.2020-10-1541 minMedEdTalks - OphthalmologyEffect of Subretinal Fluid on Visual Outcomes in Neovascular AMDThe integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Dante Pieramici discuss the effect of subretinal fluid on visual...2020-06-2914 minMedEdTalks - OphthalmologySustained Suppression of VEGF – What is the Effect? Where is the Evidence?The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Dante Pieramici discuss the potential effects of sustained vascular endothelial...2020-06-2916 minMedEdTalks - OphthalmologyEffective Treatment Interval Extensions in Neovascular Retinal DiseaseThe integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Charles Wykoff discuss effective treatment interval extensions in neovascular retinal...2020-06-2914 minMedEdTalks - OphthalmologyInhibition of Ang-2: Potential Effect in DME Treatment ParadigmsThe integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Jeffrey Heier discuss inhibition of angiopoietin-2 and its potential effect...2020-06-2914 minMedEdTalks - OphthalmologyInhibition of Ang-2: Potential Effect in AMD Treatment ParadigmsThe integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Jeffrey Heier discuss inhibition of angiopoietin-2 and its potential effect...2020-06-2913 minMedEdTalks - OphthalmologyDrug Delivery Systems in Neovascular Retinal DiseaseThe integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Charles Wykoff discuss emerging drug delivery systems for the management...2020-06-2915 min
American Academy of Ophthalmology PodcastsOcular Disease in the Older Population: Update on Age-Related Macular DegenerationHost Neil Bressler, MD, discusses macular degeneration with Carl Regillo, MD, and George Williams, MD. The conversation considers the AREDS vitamin formula, how to monitor disease risk and approach treatment options, and finally how to help patients and their families cope with potential vision loss. (October 2009)2009-12-1000 min